Cytokinetics, Incorporated (CYTK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

SA Transcripts 162.14K Followers Follow Cytokinetics, Incorporated ( CYTK ) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 3:00 PM EDT Company Participants Robert I. Blum - CEO, President & Director Daniel Jacoby - Vice President of Clinical Research Tricia Ottaviani - SVP of U.S. and Global Marketing & Operations Sung Lee Conference Call Participants Eric Joseph - Citigroup Inc., Research Division Presentation Eric Joseph Citigroup Inc., Research Division Welcome again to Citi's Back to School Biopharma Conference. I'm Eric Joseph, senior biotech analyst with Citi. And our session this afternoon is with Cytokinetics, and I'm delighted to be joined by Robert Blum and several members of the Cytokinetics team. Thank you all for joining us today. Rob, maybe, Robert, just before hopping into Q&A, I can have you start out with some high-level remarks, and then we'll go from there. Robert I. Blum CEO, President & Director So thank you, and thanks for inviting us to participate in this Back to School Event. It's our first opportunity to interact with investors in person after returning from Munich, where data from ACACIA-HCM were presented to a very, very large congress hall very, very well attended and positive reception on the part of cardiologists there attending that conference in Munich. And those results from ACACIA, we believe, provide a very important milestone and catalyst for what could be additional value creation that may come our way as that could be data incorporated into a submission for FDA and other regulatory authorities review and potential approval and ultimately enable MYQORZO to be the first cardiac myosin inhibitor approved across the full spectrum of HCM patients. Why does that matter? Because we're already demonstrating with our commercial launch of MYQORZO in oHCM that it is rapidly ascending and where we've pointed to by the end of the year, we expect to see